Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPOR | P19235 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330907 | 0.90 | LMNA (0.74) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL25370754 | 0.89 | LMNA (0.72) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL23451303 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL16295008 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL18886422 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL31097862 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL18886394 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL30783527 | 0.85 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL17841845 | 0.84 | LMNA (0.68) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL25933063 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHTTEPORL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | SMN1; SMN2 4335/4885LMNA 493/4885HTT 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.